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Abstract
Background Diabetes is an important global disease,
associated with significant morbidity and an increased risk
of death due to chronic end-organ complications. The
thiazolidinediones, used mainly as third-line agents in type
2 diabetes mellitus (T2DM), have been associated with
some safety concerns, such as an increased risk of bladder
cancer, an increased risk of bone fracture and heteroge-
neous effects on cardiovascular events.
Objective This study aimed to evaluate safety data on
pioglitazone for several outcomes and examine them in
context with each other as well as with insulin, another
third-line treatment for T2DM.
Methods This retrospective cohort study extracted data
from May 1, 2000 until June 30, 2010, from the i3 InVision
Data MartTM database. To adjust for the testing of multiple
hypotheses, the Holm method was applied to endpoints rep-
resenting potential harm from pioglitazone treatment, sepa-
rately from those representing potential benefit from
pioglitazone. The study population included patients with
T2DM C 45 years old who were new users of either piog-
litazone or insulin. Key outcomes were incident cases of a
composite of myocardial infarction (MI) or stroke requiring
hospitalization; bone fracture requiring hospitalization;
bladder cancer; and a composite of nine other selected can-
cers. Kaplan–Meier curves were generated and hazard ratios
(HRs) for pioglitazone versus insulin were estimated from Cox
proportional hazards models adjusted with inverse probability
of treatment weights derived from propensity scores.
Results A total of 56,536 patients (pioglitazone group
38,588; insulin group 17,948) qualified for the study. The
mean follow-up was 2.2 years for pioglitazone and
1.9 years for insulin patients. Weighted survival analysis of
the composite of MI and stroke, as well as the composite of
nine cancers, yielded significant differences in favour of
pioglitazone. For the composite of MI and stroke, the HR
for pioglitazone versus insulin was 0.44 (95 % confidence
interval [CI] 0.39–0.50, p \ 0.0001). Modelling of the
composite of nine selected cancers produced an HR of 0.78
(95 % CI 0.71–0.85, p \ 0.0001). A non-statistically sig-
nificant difference in favour of pioglitazone was observed
in the incidence rate of bone fracture requiring hospital-
ization (HR 0.86, 95 % CI 0.74–1.01, p = 0.058). For
bladder cancer, the overall incidence rates were relatively
low and showed no significant difference between the two
groups; the HR for pioglitazone versus insulin was 0.92
(95 % CI 0.63–1.33, p = 0.64).
Conclusion Compared with insulin, pioglitazone was
associated with a significant reduction in the risk of MI and
stroke requiring hospitalization, and a significant reduction
in the risk of other selected cancers. While pioglitazone
treatment may be linked with a lower risk of bladder cancer
and bone fracture relative to insulin, these differences were
not statistically significant.
1 Introduction
The seventh leading cause of death in the US, type 2 dia-
betes mellitus (T2DM) increases the risk of mortality from
causes such as vascular disease—in particular, coronary
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heart disease [1]. A recent publication showed that after
adjustment for age, sex, smoking status and body mass
index, diabetics, compared with non-diabetics, have hazard
ratios (HRs) of 1.25 for death from cancer, 2.32 for death
from vascular causes and 1.73 for death from other causes
[2]. This same study also found that diabetes was associ-
ated with substantial premature mortality from infectious
diseases and degenerative conditions.
The thiazolidinediones (TZDs), rosiglitazone and piog-
litazone, are synthetic ligands for peroxisome proliferator-
activated receptors (PPARs) that alter the transcription of
genes influencing carbohydrate and lipid metabolism [3].
Both TZDs improve insulin sensitivity through their action
at PPAR gamma receptors—with similar effects on glucose
levels—but pioglitazone demonstrates a different effect on
lipid metabolism [4, 5] and further has been associated
with a reduction in the risk of hospitalization for acute
myocardial infarction (AMI) compared with rosiglitazone
[6]. Results from the PROactive (PROspective pioglitAz-
one Clinical Trial In macroVascular Events) study have
shown that pioglitazone, in conjunction with standard
treatments for diabetes and cardiovascular (CV) conditions,
can reduce the risk of the composite endpoint of all-cause
mortality, non-fatal myocardial infarction (MI) and stroke
[7]. Regarding insulin, attention has been drawn to the
potential link between hyperinsulinization and CV events
[8].
Animal toxicity studies have both suggested a possible
increased cancer risk in multiple organs in association with
a wide variety of PPAR modulators such as pioglitazone
[9] and, in contrast, attributed PPAR gamma activators
with inhibitory effects on tumour development [10]. Few
clinical trials or epidemiological data have provided
information on PPAR modulators and the risk of cancer in
association with their use [11]; conversely, insulin has been
studied for decades and is posited to exhibit mitogenic
effects on cancer tumours [12]. In addition, pioglitazone
has been associated with bone fracture in postmenopausal
women [13] but, again, clinical studies to date on PPAR
modulators and bone fracture have been rare.
Requests from regulatory bodies have led to research,
initiated in 2003, to corroborate a possible increased risk of
cancer with pioglitazone, addressing cancer in general and
bladder cancer in particular. Interim results have shown no
evidence of an association between the use of pioglitazone
and the risk of cancer at the ten most common cancer sites,
compared with use of other oral anti-diabetic agents [11].
Moreover, any use of pioglitazone was not associated with
an increased incidence of bladder cancer, although use for
more than 2 years was weakly associated with an increased
risk [14, 15]. Recently published studies have offered an
array of results and inferences regarding this topic [16–18].
A public–private enterprise assembled to help improve the
monitoring of drugs for safety, the Observational Medical
Outcomes Partnership (OMOP), has found that the choices
made during an observational study, regarding the design,
database, comparator and covariates, can drastically alter
results of research focusing on a specific drug/outcome pair
[19].
Pioglitazone and insulin have never been directly com-
pared in any published literature, even though it is a natural
comparison, given that both treatments occur at roughly the
same stage of the progression of diabetes as a disease—as
shown, for example, in the Comprehensive Diabetes
Management Algorithm under dual therapy and triple
therapy [20]. Pioglitazone is typically used as a third-line
therapy following failure of metformin and/or sulfonylurea,
while insulin is commonly used after failure of mono- and
dual-diabetes therapy. This observational study aims to fill
that gap, by investigating and putting into context event
rates for a range of outcomes, from cancer to bone fracture
to cardiovascular events, for both treatments. These end-
points and their relationship to pioglitazone have been
analyzed separately in the past few years; bringing them
together in one study can sharpen the focus on the relative
benefits and risks associated with pioglitazone.
2 Methods
2.1 Study Design
This retrospective cohort study, abiding by a documented
pre-specified protocol (available from the authors upon
request), extracted data from May 1, 2000 until June 30,
2010, from the i3 InVision Data MartTM. The i3 database
contains longitudinal health claims from approximately 47
million participants with both medical and prescription drug
coverage under the United Healthcare insurance plans in the
US. Because of the non-interventional nature of the study, no
ethical approval or informed patient consent were sought.
2.2 Patient Selection
The index date was defined as the first claim date of the
index medication (pioglitazone or insulin) between January
1, 2003 and December 31, 2008, and was considered the
first day of follow-up. The period of at least 180 days
before the index medication was defined as the baseline
period. A minimum of 28 days from the index date to the
end of insurance eligibility or the end of the study period
(June 30, 2010)—whichever came first—comprised the
follow-up period. Although the database does not specifi-
cally record death, the decease of a patient during follow-
up would have resulted in censoring due to the patient’s
loss of insurance eligibility.
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The study population consisted of patients with T2DM,
identified using International Classification of Diseases
(ICD)-9 diagnosis codes 250.x0 or 250.x2, and divided into
two groups: new users of any pioglitazone-containing
products and new users of any insulin-containing products
(n = 716,831 included). All patients were C45 years of
age (n = 119,423 excluded), had relevant insurance
enrolment periods and claims (n = 299,736 excluded) and
met minimum requirements for the baseline and follow-up
periods (n = 133,334 excluded). Other exclusion criteria
included type 1 diabetes mellitus, type 2 gestational dia-
betes, diabetes insipidus or renal glycosuria (n = 23,704),
and use of rosiglitazone-containing products at any time
(n = 63,388). Patients who switched from one index
medication to the other, or who took both drugs simulta-
neously, were excluded (n = 8,549), as were patients with
only one claim for either pioglitazone or insulin within
6 months of the index date (n = 12,161), leaving the study
with 38,588 pioglitazone patients and 17,948 insulin
patients.
Also excluded from specific endpoint analyses were
patients who experienced any relevant incident outcomes
during the baseline period: for the cardiovascular (CV)
endpoint analysis, patients with a corresponding CV event
within 28 days prior to the index date (n = 1,200) were
excluded; for the bone fracture endpoint analysis, patients
with a bone fracture within 360 days prior to the index date
(n = 1,818) were excluded; for any cancer endpoint anal-
ysis, patients with a diagnosis of any cancer prior to the
index date (n = 6,961) were excluded. Allowing for a
28-day baseline exclusionary period for a CV event, or
even a 1-year period for bone fracture, does not fit the
traditional definition of incidence. However, use of such
conservative exclusion criteria maximizes the number of
patients in the study and the total count of events—two
prime considerations.
2.3 Statistical Analysis
Propensity scores were used to alleviate concerns about the
introduction of bias due to differences in baseline covari-
ates between the two treatment cohorts [21, 22]. Although
matching was an option, weights based on propensity
scores additionally serve to allay some researchers’
apprehension that matching might exclude a substantial
sample size of patients whose disease experience could
make a valid contribution. Considering weights based on
both the standardized morbidity ratio [23] and the inverse
probability of treatment (IPT) [24, 25], we opted for the
latter. These weights yield cohorts that are effectively from
a common population, except for the difference in the
propensity score response variable—in our case, the index
medications.
A wealth of baseline data included demographics (age,
sex, tobacco use), use of medications (defined as any pre-
scription claim within 180 days prior to the index date) and
medical history (defined as any diagnosis claim prior to the
index date). These variables were chosen based on a priori
considerations of clinical significance in relation to the
risks of cardiovascular events, bone fracture and bladder
cancer. The final list of covariates used to estimate the
propensity scores was based on a stepwise logistic
regression model, with p \ 0.2 to enter the model and
p \ 0.05 to remain (age and sex remained, regardless of
the p value). Roughly 30 of the more than 40 independent
variables fitted were retained by each model.
2.3.1 Outcome Measures
The study focused on incident cases of four major end-
points: a composite of MI or stroke requiring hospitaliza-
tion; bone fracture requiring hospitalization; bladder
cancer; and a composite of the nine most common cancers,
excluding bladder cancer (prostate, female breast, lung/
bronchus, pancreatic, endometrial, non-Hodgkin’s lym-
phoma, colorectal, kidney and malignant melanoma). All
ICD-9 diagnosis codes listed in Table 1 were carefully
chosen in the study design stage. Validated coding algo-
rithms for the outcomes were selected when available in
the literature. For example, ICD-9 codes for incident MI
and stroke have been validated against medical charts with
high positive predictive values [26, 27]. To verify the
findings based on incident cases of bladder cancer, a sec-
ondary analysis was performed using additional therapy
codes and procedures to confirm the presence of cancer,
such as radiation treatment, chemotherapy, cystoscopy or
cystectomy.
Each outcome used a unique, conservative drug residual
effect period based on the clinical course of the specific
disease, which was equivalent to the baseline exclusionary
period: 28 days for CV events and 360 days for bone
fracture events; there was no time limit on the occurrence
of any cancer events. Hence CV and bone fracture out-
comes recorded after this pre-specified period following
the last day of the last prescription were deemed unrelated
to treatment.
2.3.2 Modelling and Testing
Analyses were performed separately on the first occurrence
of each major endpoint. The time to event spanned from
the index date until the earliest of the following: the first
event date; the last day of the drug residual effect period; or
the patient’s last day of insurance eligibility.
The hazard ratios of pioglitazone over insulin and 95 %
confidence intervals (CIs) were estimated from Cox
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proportional hazards models using IPT weights. Crude
event rates across time were also calculated. Unweighted
Cox regression models using the propensity score as a
covariate, as well as the full set of covariates, were fitted as
sensitivity checks on the results from modelling with
inverse probability weights, yielding very similar HRs. The
proportional hazards assumption was verified through the
graphical and re-sampling techniques of Lin et al. [28] and
by plotting the log of cumulative hazard vs. log of time.
Analyses were conducted using SAS version 9.1 software
(SAS Institute, Cary, NC, USA).
To adjust for the multiplicity of hypothesis tests, a
twofold approach to control the overall probability of a
type I error was decided upon during the design phase of
the study. The CV endpoint, representing potential benefit
from pioglitazone in comparison with insulin, would be
treated separately and tested at the 0.05 significance level
(two-sided). The three other major endpoints, representing
potential risks from pioglitazone treatment, would be
adjusted for multiplicity using the Holm method [29], also
at the 0.05 level.
3 Results
3.1 Baseline
Table 2 presents a summary of demographics for the
38,588 pioglitazone and 17,948 insulin users who fulfilled
the inclusion and exclusion criteria. First prescriptions of
pioglitazone were evenly dispensed throughout the study
period, with a slight increase in later years, while one third
of first prescriptions for insulin were dispensed in the last
year. Differences in the medical conditions that were pre-
valent in the pioglitazone and insulin groups were
observed. With the exceptions of hyperlipidaemia and
hypertension, which were recorded in greater proportions
of patients in the pioglitazone group, all other medical
conditions were observed in larger percentages of patients
receiving insulin.
Similarly, the majority of dispensed drugs were used by
greater proportions of patients in the insulin group. The
effect of the IPT weights used to balance the cohorts with
respect to these differences can be seen in Table 2. Com-
pared with the unweighted p values, all of the covariates—
save two at the 0.05 level, or four at the 0.10 level—were
successfully balanced by the weighting technique. Given a
list of more than 40 covariates, and the significant multi-
plicity that such a list entails, it is to be expected that some
would remain unbalanced even after weighting. As a sen-
sitivity check, these covariates were added to the Cox
regressions, with no change in the treatment effect.
3.2 Raw Incidence
The mean follow-up time was 2.2 years in the pioglitazone
group and 1.9 years in the insulin group, with some
patients being followed up for as long as 7 years. The
average raw incidence rates for pioglitazone and insulin for
each major endpoint are shown side by side in Fig. 1.
Relative to the other endpoints, bladder cancer had
substantially lower incidence rates: 113 and 152 per
100,000 person-years for pioglitazone and insulin, respec-
tively. The cancer composite had the highest incidence
rates: 1,798 for pioglitazone, 2,456 for insulin. Pioglitaz-
one also had lower incidence rates than insulin for the
composite of MI and stroke (717–2,067) and bone fracture
(581–959 per 100,000 person-years).
Note that the average raw incidence rates of the com-
posite of nine other selected cancers for both pioglitazone
and insulin were 16 times higher than the respective rates
of bladder cancer alone. Bone fracture and the CV com-
posite rates ranged from 5 to 13 times the rate of bladder
cancer.
3.3 Modelling
3.3.1 Composite of MI and Stroke
For the composite of MI and stroke, the HR for pioglit-
azone versus insulin from a Cox regression using IPT
weights was 0.44 (95 % CI 0.39–0.50, p \ 0.0001)
[Fig. 2a shows the Kaplan–Meier event-free probability
curves]. MI and stroke endpoints were then tested indi-
vidually: the HRs of pioglitazone versus insulin were 0.49
Table 1 International Classification of Diseases (ICD)-9 codes for
major endpoints and their components
Endpoint ICD-9 code
MI 410.xx
Stroke 430, 431, 433.x1
434.xx (excluding 434.x0), 436
Bone fracture 800.xx–829.xx
Bladder cancer 188.xx, 233.7
Prostate cancer 185.xx, 233.4
Female breast cancer 174.xx, 233.0
Lung cancer 162.x, 231.1, 231.2
Pancreatic cancer 157.x (excluding 157.4)
Endometrial cancer 179, 182.x
Non-Hodgkin’s lymphoma 200.xx, 202.xx
Colorectal cancer 153.x, 154.0, 154.1, 230.3, 230.4
Kidney cancer 189.x (excluding 189.3 and 189.4)
Malignant melanoma 172.x, 232.x
MI myocardial infarction
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Table 2 Patient demographics and baseline covariates
Patient characteristic Pioglitazone, n = 38,588 Insulin, n = 17,948 Unweighted p valuea Weighted p valueb
Age
Mean [years (SD)] 58.1 (8.7) 59.7 (10.3) \0.0001 0.8064
Median [years] 57 58
45–54 years [n (%)] 14,490 (37.6) 6,432 (35.8)
55–64 years [n (%)] 16,618 (43.1) 6,929 (38.6)
65–74 years [n (%)] 5,371 (13.9) 2,685 (15.0)
75–80 years [n (%)] 1,325 (3.4) 976 (5.4)
80? years [n (%)] 784 (2.0) 926 (5.2)
Male sex [n (%)] 22,981 (59.6) 9,504 (53.0) \0.0001 0.1828
Year of drug initiation [n (%)]
2003 4,734 (12.3) 1,989 (11.1) \0.0001 0.8908
2004 5,292 (13.7) 2,137 (11.9)
2005 6,916 (17.9) 2,581 (14.4)
2006 7,915 (20.5) 2,321 (12.9)
2007 5,591 (14.5) 2,923 (16.3)
2008 8,140 (21.1) 5,997 (33.4)
Medical conditions [n (%)]
Obesity 5,798 (15.0) 2,831 (15.8) 0.0213 0.1356
Hyperlipidaemia 30,410 (78.8) 11,608 (64.7) \0.0001 0.1308
MI 1,677 (4.3) 1,615 (9.0) \0.0001 0.6195
Coronary heart disease 7,576 (19.6) 4,998 (27.8) \0.0001 0.8043
Coronary revascularization 1,482 (3.8) 1,201 (6.7) \0.0001 0.7295
Stroke 3,041 (7.9) 2,573 (14.3) \0.0001 0.9425
Congestive heart failure 1,846 (4.8) 3,029 (16.9) \0.0001 0.7792
Hypertension 29,641 (76.8) 13,498 (75.2) \0.0001 0.8608
Arrhythmias 3,737 (9.7) 3,378 (18.8) \0.0001 0.6126
Smoking 3,289 (8.5) 2,148 (12.0) \0.0001 0.8784
Cancer 4,171 (10.8) 2,790 (15.5) \0.0001 0.9210
Bone fracture 2,231 (5.8) 1,423 (7.9) \0.0001 0.8626
Renal impairment 2,503 (6.5) 3,112 (17.3) \0.0001 0.7158
Gout 1,737 (4.5) 861 (4.8) 0.1179 0.6195
Dispensed anti-diabetic drugs [n (%)]
Metformin 15,153 (39.3) 5,991 (33.4) \0.0001 0.0530
Sulfonylureas 12,670 (32.8) 6,972 (38.8) \0.0001 \0.0001
Meglitinides 576 (1.5) 441 (2.5) \0.0001 0.6847
DPP-4 652 (1.7) 614 (3.4) \0.0001 0.4871
GLP 356 (0.9) 629 (3.5) \0.0001 0.3002
Other anti-diabetic drugs 95 (0.2) 135 (0.8) \0.0001 0.4840
Other dispensed drugs [n (%)]
Nitrates 1,206 (3.1) 1,067 (5.9) \0.0001 0.8258
b-blockers 8,901 (23.1) 4,860 (27.1) \0.0001 0.7236
Calcium channel blockers 6,341 (16.4) 3,243 (18.1) \0.0001 0.4789
Diuretics 6,828 (17.7) 4,688 (26.1) \0.0001 0.8243
ACE inhibitors/ARBs 19,289 (50.0) 7,840 (43.7) \0.0001 0.6690
Antilipaemic agents 18,922 (49.0) 6,652 (37.1) \0.0001 0.1827
Aspirin/NSAIDs 5,840 (15.1) 2,195 (12.2) \0.0001 0.1639
Anticoagulants 977 (2.5) 1,070 (6.0) \0.0001 0.5117
Antiplatelets 1,186 (3.1) 851 (4.7) \0.0001 0.5619
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(95 % CI 0.41–0.57, p \ 0.0001) for MI and 0.37 (95 % CI
0.31–0.45, p \ 0.0001) for stroke. The incidence rates,
HRs and p values by endpoint are reported in Table 3.
A plot of the raw incidence rates of the composite of MI
and stroke by year is shown in Fig. 2b. Over the first
6 years, incidence rates were greater in the insulin group;
in year 7, the incidence of the CV composite was greater in
the pioglitazone group, although the sample size for that
year was very small (pioglitazone n = 115, insulin
n = 50). The vertical bars at each year represent pointwise
95 % CIs—derived from the Poisson distribution—to
illustrate the inherent variability in the data, which was
especially high in later years when the sample sizes were
drastically reduced. To preserve a uniform, reasonable rate
scale for all endpoints, the graphs cut off the upper bounds
of some confidence intervals at 3,000.
3.3.2 Multiple Hypothesis Tests for Cancers and Bone
Fracture
The three p values corresponding to the primary endpoints
representing potential risks from pioglitazone treatment
were tested in order according to the Holm method. The
smallest belonged to the cancer composite and was tested
first. This HR was 0.78 (95 % CI 0.71–0.85), with a p value
below 0.0001—highly statistically significant and well
below 0.05/3 or 0.0167 (the allotted significance level).
This enabled hypothesis testing to continue. The second
smallest p value belonged to bone fracture with hospital-
ization, with an HR of 0.86 (95 % CI 0.74–1.01) and a
p value of 0.058. The p value was larger than 0.025 (the
allowed significance level) and therefore not significant.
Thus, the testing procedure was stopped, and the p value
for bladder cancer was automatically declared not
significant.
3.3.3 Cancer Composite
The Kaplan–Meier curves for the composite of nine
selected cancers appear in Fig. 3a. The raw incidence rate
of the composite cancer endpoint was greater in the insulin
group in each of the first 5 years of follow-up (Fig. 3b). As
reported under ‘Composite of MI and Stroke’, the later
years of observation were prone to progressively higher























Fig. 1 Raw incidence rates for the four major study endpoints,
illustrating the relatively low incidence of bladder cancer and the
differences in incidence between pioglitazone and insulin. PY person-
years
Table 2 continued
Patient characteristic Pioglitazone, n = 38,588 Insulin, n = 17,948 Unweighted p valuea Weighted p valueb
Anti-epileptic agents 2,029 (5.3) 1,664 (9.3) \0.0001 0.9523
SSRIs 3,832 (9.9) 2,323 (12.9) \0.0001 0.8897
Lithium 73 (0.2) 33 (0.2) 0.8919 0.2322
Proton pump inhibitors 4,872 (12.6) 2,831 (15.8) \0.0001 0.3612
Bisphosphonates 686 (1.8) 355 (2.0) 0.0993 0.0480
Fluoride 11 (0.0) 7 (0.0) 0.5150 0.9052
Aromatase inhibitors 122 (0.3) 76 (0.4) 0.0444 0.7692
SERMs 258 (0.7) 65 (0.4) \0.0001 0.8935
Parathyroid hormone analogues 54 (0.1) 54 (0.3) \0.0001 0.0662
Immunosuppressors 4,823 (12.5) 3,502 (19.5) \0.0001 0.9309
Estrogens (systemic) 1,644 (4.3) 589 (3.3) \0.0001 0.7314
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, DPP-4 dipeptidyl peptidase-4, GLP glucagon-like peptide, MI myo-
cardial infarction, NSAID non-steroidal anti-inflammatory drug, SD standard deviation, SERM selective estrogen receptor modulator, SSRI
selective serotonin reuptake inhibitor
a Cohort comparison based on a v2 test for categorical variables and analysis of variance for continuous variables
b Cohort comparison weighted by inverse probability of treatment. Weights were derived from propensity scores adjusted for all baseline
variables (age was a continuous covariate)
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3.3.4 Bone Fracture
The incidence rates of bone fracture requiring hospital-
ization were largely similar between the two groups
throughout the follow-up period.
3.3.5 Bladder Cancer
Based on a scant 84 events from the pioglitazone arm and
44 from the insulin arm, the event-free probability of
bladder cancer was similar in the two groups and remained
above 0.99 at 5.8 years, the time of the last event (not
shown). The HR for pioglitazone versus insulin was 0.92
(95 % CI 0.63–1.33, p = 0.64). The incidence rates of
bladder cancer were low and similar in the pioglitazone and
insulin groups (Fig. 4). Furthermore, there was no evidence
of an increasing risk of bladder cancer over time due to the
use of pioglitazone. A secondary analysis, designed to
further confirm the presence of bladder cancer through
additional therapy codes and procedures, produced similar
results (Table 3).
3.3.6 Individual Cancers and Other Secondary Endpoints
The HRs for secondary endpoints, such as individual can-
cers and bone fracture not requiring hospitalization, are
also shown in Table 3. Patients in the pioglitazone group
showed markedly lesser risks of prostate cancer, lung
cancer, pancreatic cancer and colorectal cancer, compared
with those in the insulin group. Female breast cancer,
endometrial cancer and kidney cancer, as well as malignant
melanoma, showed similar incidence rates in both groups,
while the HR for non-Hodgkin’s lymphoma favoured the



























Patients at risk (unweighted)
38,205      23,069      12,636         6,375          3,173        1,303            545             115      Pioglitazone



























Fig. 2 a Kaplan–Meier event-
free probability curves for time
to myocardial infarction (MI) or
stroke; b raw incidence rates of
the composite of MI and stroke.
The vertical bars at each year
represent pointwise 95 %
confidence intervals (CIs)
derived from the Poisson
distribution, cut off at 3,000 in
order to preserve a uniform,
reasonable rate scale for all
endpoints. PY person-years
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could be declared statistically significant, because the type
1 error (a) had already been ‘spent’ during the primary
endpoint analysis.
4 Discussion
This retrospective cohort study used health claims from the
i3 InVision Data MartTM to conclude that, in a comparison
between third-line anti-diabetic agents pioglitazone and
insulin, the risk of MI or stroke was 56 % lower in the
pioglitazone group, while the risk of nine selected cancers
was 22 % lower. Models for bone fracture requiring hos-
pitalization and bladder cancer also yielded hazard ratios in
favour of pioglitazone; however, the differences between
the two treatment groups were not significant. The fitted
Cox regressions used IPT weights derived from propensity
scores adjusted for a multitude of confounding variables—
including age, sex, baseline comorbidities and medications.
Various sensitivity analyses confirmed the results.
One particular sensitivity analysis merits special atten-
tion. Rather than excluding patients who switched index
treatments, or who ever took rosiglitazone, follow-up time
was censored either at the point when the patient switched or
at the point when the patient started on rosiglitazone. Patients
who took rosiglitazone before taking the index medication
were again excluded. This scheme added about 7,500
patients to the overall population, of whom roughly 5,500
were in the pioglitazone cohort. This alternative analysis
followed an intent-to-treat design and allocated events to the
original treatment—for example, patients who were on
pioglitazone for a few months before switching to insulin,
then a few years later developed cancer, would be counted as
pioglitazone events. The effects of the revised design were to
slightly increase the pioglitazone incidence rates, slightly
lower the insulin incidence rates and shift the hazard ratios
somewhat towards the null. The CV and cancer composite
HRs were about 0.10 higher; the bone fracture HR went up by
0.05 and the bladder cancer HR by 0.01. But the results of the
hypothesis tests were not altered, and the overall observa-
tions and general conclusions remained unchanged.
A recent study that focused on bladder cancer studied two
US-based cohorts from the Kaiser Permanente Northern
California (KPNC) database, comprising 30,173 patients
treated with pioglitazone and 162,926 patients who had
never received pioglitazone [14, 15]. Overall, the results
showed a lack of association between pioglitazone and the
risk of bladder cancer; however, there was a weak associa-
tion between the risk of bladder cancer and increasing
duration of pioglitazone use, as is currently documented on
Table 3 Raw average incidence rate and adjusted hazard ratios (HRs) by endpoint





Pioglitazone, n = 38,588 Insulin, n = 17,948
Primary endpoints
Composite of MI and stroke with hospitalization 717 (472) 2,067 (554) 0.44 (0.39–0.50) \0.0001
Composite of nine other selected cancers 1,798 (1,305) 2,456 (689) 0.78 (0.71–0.85) \0.0001
Bone fracture with hospitalization 581 (424) 959 (287) 0.86 (0.74–1.01) 0.0577
Bladder cancer 113 (84) 152 (44) 0.92 (0.63–1.33) 0.6405
Secondary endpoints
MI with hospitalization 454 (301) 1,155 (318) 0.49 (0.41–0.57) \0.0001
Stroke with hospitalization 271 (180) 959 (265) 0.37 (0.31–0.45) \0.0001
Bone fracture not requiring hospitalization 2,926 (2,066) 4,033 (1,162) 0.91 (0.84–0.98) 0.0122
Bladder cancer with confirmation 85 (63) 111 (32) 0.93 (0.61–1.44) 0.7502
Prostate cancer 787 (346) 923 (138) 0.82 (0.68–0.997) 0.046
Female breast cancer 609 (181) 826 (113) 0.85 (0.67–1.08) 0.1748
Malignant melanoma 372 (276) 431 (124) 0.83 (0.67–1.02) 0.0783
Colorectal cancer 194 (144) 326 (94) 0.67 (0.52–0.86) 0.0021
Non-Hodgkin’s lymphoma 187 (139) 197 (57) 1.15 (0.84–1.58) 0.3780
Lung cancer 169 (126) 308 (89) 0.59 (0.45–0.77) 0.0001
Kidney cancer 103 (77) 138 (40) 0.87 (0.59–1.27) 0.4575
Pancreatic cancer 67 (50) 214 (62) 0.30 (0.21–0.44) \0.0001
Endometrial cancer 60 (45) 100 (29) 0.80 (0.49–1.30) 0.3612
CI confidence interval, MI myocardial infarction
a HR from Cox regression adjusted with inverse probability of treatment weights
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the Actos prescribing information [13]. It should be pointed
out that the KPNC study reached its conclusion based on
fitted exposure to pioglitazone and that patients on pioglit-
azone averaged 3.7 years of follow-up, whereas the current
study considered raw pioglitazone follow-up time averaging
2.2 years. KPNC registry data showed that the unadjusted
incidence rates of bladder cancer in patients who had ever
used, or never used, pioglitazone were 81.5 and 68.8 per
100,000 person-years, respectively, closely approximated by
the current study’s rate of bladder cancer with confirmation
(Table 3) and comparable to those published on the Sur-
veillance Epidemiology and End Results (SEER) [30]
website for 2000–2008.
Studies performed in European databases have recently
appeared. A cohort study of the French national health
insurance database found a significant association between
exposure to pioglitazone and bladder cancer among 40- to
79-year-olds, albeit with an incidence rate of 49 per 100,000
person-years [16]. A nested case-control study conducted in
the UK’s General Practice Research Database (GPRD)
concluded that while the odds ratio was relatively high, the
risk of bladder cancer associated with pioglitazone was low
in absolute terms [17]. Propensity score matching was used
in a cohort study of diabetic patients in the same GPRD and
showed that pioglitazone did not significantly increase the
risk of bladder cancer compared with other anti-diabetic
medications [18]. The results from the current study also
complement recent findings from a cohort study looking at
the risk of incident cancer in patients treated with pioglit-
azone [12]. Insulin is theorized to stimulate cancer cell
proliferation and metastasis [31], although the recent
ORIGIN (Outcome Reduction with an Initial Glargine
Intervention) trial found a neutral relationship between
insulin and both cancer and CV outcomes [32].
The event data for MI and stroke in the current study fall
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Fig. 3 a Kaplan–Meier event-
free probability curves for the
composite endpoint of nine
cancers; b raw incidence rates
of the composite endpoint of
nine cancers. The vertical bars
at each year represent pointwise
95 % confidence intervals (CIs)
derived from the Poisson
distribution, cut off at 3,000 in
order to preserve a uniform,
reasonable rate scale for all
endpoints. PY person-years
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cohort study, which investigated the risk of AMI during
2003–2006, found that the crude incidence rates of MI
were 933 for pioglitazone and 1,113 per 100,000 person-
years for rosiglitazone patients [6]. The current study’s rate
of MI, covering 2003–2010, was 454 per 100,000 person-
years (Table 3), in agreement with a recognized—but not
well understood—trend of a decline in CV events in recent
years [33, 34]. A systematic review of Medline and EM-
BASE records for randomized, controlled studies of vari-
ous drugs, with [1,000 diabetic subjects, found that the
weighted mean incidence rates of MI and stroke were 520
and 540 per 100,000 person-years, respectively [35].
An increased risk of bone fractures is also associated
with diabetes [36–41]; a higher incidence of fractures has
been reported in patients who were treated with insulin in
comparison with T2DM patients who were not [36, 37].
Thiazolidinediones have also been associated with an
increased risk of bone fracture [42–44]. A study that used
the self-controlled case-series model in the UK compared
rates of fracture during TZD exposure with unexposed
periods, and found a within-person rate ratio of 1.43 (95 %
CI 1.25–1.62) for fracture at any site. This association was
similar in men and women, and in patients treated with
either rosiglitazone or pioglitazone [42].
The current study required that patients have a baseline
period of at least 6 months, enabling a reliable definition of
the index medication. However, the relatively short pre-
baseline period available in the database made it very diffi-
cult to reliably estimate the duration of diabetes based on
claims. The exclusion of this variable should have been
indirectly offset by the extensive list of comorbidity condi-
tions and baseline medications used in the regression model.
This study had other limitations. Lack of randomization
entails a risk of confounding due to unbalanced selection of
patients, although the Cox model with IPT weights derived
from a list of more than 40 confounding variables eliminated
some potential bias. The relatively short follow-up average
of about 2 years meant that the effects of long-term treatment
could not be reliably assessed by this study; such assessments
must be left to future, longer-term studies. In addition,
patients over 65 years of age may have been missed, as most
would have transferred to the US Medicare program and
would then have been lost from the claims database, sug-
gesting a potential bias in the current study towards a
younger cohort. Also, patients who took both pioglitazone
and insulin—who might generally have been in poorer health
than the included patients or may have had contraindications
to one of the two treatments—were excluded, which led to a
slight under-estimation of the incidence rate in the pioglit-
azone cohort, as demonstrated by a sensitivity analysis.
5 Conclusion
This study found that the risks of two composite endpoints—
one for cardiovascular events, the other for nine cancer
sites—were significantly lower among patients exposed to
pioglitazone than among those exposed to insulin. While the
risks of bone fracture and bladder cancer were lower in the
pioglitazone group, the differences were not statistically
significant. Among the major endpoints, bladder cancer had
by far the lowest risk—one-sixteenth that of the composite of
nine cancers—and showed no evidence of its incidence rate
increasing with duration of exposure to pioglitazone.
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